TRENTON, N.J. (AP) — New Jersey’s Supreme Court has dismissed more than 500 lawsuits against the maker of an acne drug that caused some patients to develop a gastrointestinal disease.
The court ruled Wednesday that Hoffmann-LaRoche’s warning labels for its Accutane treatment were adequate.
Plaintiffs have contended the warnings should have said Accutane “causes,” rather than “is associated with,” inflammatory bowel disease.
A trial court had dismissed the suits in 2015, but an appeals court had reinstated most of them.
The Supreme Court also ruled the 532 product-liability claims from patients in multiple states were properly consolidated in New Jersey, where Hoffmann-LaRoche has its principal place of business.